Published in Alzheimers Dement on August 15, 2013
Imaging-based enrichment criteria using deep learning algorithms for efficient clinical trials in mild cognitive impairment. Alzheimers Dement (2015) 0.96
Use of High-Frequency In-Home Monitoring Data May Reduce Sample Sizes Needed in Clinical Trials. PLoS One (2015) 0.83
Latent Classes of Neuropsychiatric Symptoms in NACC Controls and Conversion to Mild Cognitive Impairment or Dementia. J Alzheimers Dis (2015) 0.76
Five-year biomarker progression variability for Alzheimer's disease dementia prediction: Can a complex instrumental activities of daily living marker fill in the gaps? Alzheimers Dement (Amst) (2015) 0.75
The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 21.80
The Modified Mini-Mental State (3MS) examination. J Clin Psychiatry (1987) 19.45
Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am J Public Health (1998) 9.58
Subgroup analysis, covariate adjustment and baseline comparisons in clinical trial reporting: current practice and problems. Stat Med (2002) 7.41
CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA (2009) 7.29
Using the general linear mixed model to analyse unbalanced repeated measures and longitudinal data. Stat Med (1997) 7.22
Comparing predictors of conversion and decline in mild cognitive impairment. Neurology (2010) 5.69
Rate of progression of mild cognitive impairment to dementia--meta-analysis of 41 robust inception cohort studies. Acta Psychiatr Scand (2008) 3.65
Incidence and outcome of mild cognitive impairment in a population-based prospective cohort. Neurology (2002) 3.57
Patterns of cognitive decline in presymptomatic Alzheimer disease: a prospective community study. Arch Gen Psychiatry (2001) 3.32
Temporal trends in the long term risk of progression of mild cognitive impairment: a pooled analysis. J Neurol Neurosurg Psychiatry (2008) 2.90
Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib. Arch Neurol (2008) 2.86
Alzheimer's prevention initiative: a proposal to evaluate presymptomatic treatments as quickly as possible. Biomark Med (2010) 2.17
Mild behavioral impairment and risk of dementia: a prospective cohort study of 358 patients. J Clin Psychiatry (2009) 2.16
Boosting power for clinical trials using classifiers based on multiple biomarkers. Neurobiol Aging (2010) 2.13
Sting of Alzheimer's failures offset by upcoming prevention trials. Nat Rev Drug Discov (2012) 2.02
On the efficiency of targeted clinical trials. Stat Med (2005) 1.99
Report of the task force on designing clinical trials in early (predementia) AD. Neurology (2010) 1.75
Two-year progression from mild cognitive impairment to dementia: to what extent do different definitions agree? J Am Geriatr Soc (2008) 1.74
Requiring an amyloid-beta1-42 biomarker for prodromal Alzheimer's disease or mild cognitive impairment does not lead to more efficient clinical trials. Alzheimers Dement (2010) 1.70
The 32-year relationship between cholesterol and dementia from midlife to late life. Neurology (2010) 1.64
Alzheimer's Disease Anti-inflammatory Prevention Trial: design, methods, and baseline results. Alzheimers Dement (2009) 1.28
Rapid progression from mild cognitive impairment to Alzheimer's disease in subjects with elevated levels of tau in cerebrospinal fluid and the APOE epsilon4/epsilon4 genotype. Dement Geriatr Cogn Disord (2009) 1.23
Annual rate and predictors of conversion to dementia in subjects presenting mild cognitive impairment criteria defined according to a population-based study. Dement Geriatr Cogn Disord (2004) 1.20
Effects of non-steroidal anti-inflammatory drug treatments on cognitive decline vary by phase of pre-clinical Alzheimer disease: findings from the randomized controlled Alzheimer's Disease Anti-inflammatory Prevention Trial. Int J Geriatr Psychiatry (2011) 1.16
Characteristics of a two-stage screen for incident dementia. J Clin Epidemiol (2003) 1.13
Tracking cognition-health changes from 55 to 95 years of age. J Gerontol B Psychol Sci Soc Sci (2010) 1.10
High rate of conversion to Alzheimer's disease in a cohort of amnestic MCI patients. Int Psychogeriatr (2007) 1.09
Conversion of mild cognitive impairment to dementia in elderly subjects: a preliminary study in a memory and cognitive disorder unit. Arch Gerontol Geriatr (2007) 1.08
Mild cognitive impairment in a community sample: the Sydney Memory and Ageing Study. Alzheimers Dement (2012) 1.02
Cognitive profiles of incipient dementia in the Goteborg MCI study. Dement Geriatr Cogn Disord (2010) 1.02
Prevention trials in Alzheimer's disease: an EU-US task force report. Prog Neurobiol (2011) 1.02
Enrichment through biomarkers in clinical trials of Alzheimer's drugs in patients with mild cognitive impairment. Neurobiol Aging (2010) 1.01
Conversion to dementia among two groups with cognitive impairment. A preliminary report. Dement Geriatr Cogn Disord (2004) 0.97
One size fits all? Why we need more sophisticated analytical methods in the explanation of trajectories of cognition in older age and their potential risk factors. Int Psychogeriatr (2009) 0.95
Biomarkers as predictors for conversion from mild cognitive impairment to Alzheimer-type dementia: implications for trial design. J Alzheimers Dis (2010) 0.94
How should we deal with missing data in clinical trials involving Alzheimer's disease patients? Curr Alzheimer Res (2011) 0.92
Practice effects in a longitudinal, multi-center Alzheimer's disease prevention clinical trial. Trials (2012) 0.90
Prediction of Alzheimer's disease using midregional proadrenomedullin and midregional proatrial natriuretic peptide: a retrospective analysis of 134 patients with mild cognitive impairment. J Clin Psychiatry (2010) 0.89
Requiring an amyloid-β1-42 biomarker may improve the efficiency of a study, and simulations may help in planning studies. Alzheimers Res Ther (2011) 0.88
Four-year outcome of mild cognitive impairment: the contribution of executive dysfunction. Neuropsychology (2012) 0.87
APOE ε4 increases the risk of progression from amnestic mild cognitive impairment to Alzheimer's disease among ethnic Chinese in Taiwan. J Neurol Neurosurg Psychiatry (2010) 0.84
Preclinical dementia: an Italian multicentre study on amnestic mild cognitive impairment. Dement Geriatr Cogn Disord (2007) 0.84
Use of biomarkers in clinical trials of Alzheimer disease: from concept to application. Mol Diagn Ther (2011) 0.81
Predictive utility of type and duration of symptoms at initial presentation in patients with mild cognitive impairment. Dement Geriatr Cogn Disord (2010) 0.80
Biomarker positive and negative subjects in the ADNI cohort: clinical characterization. Curr Alzheimer Res (2012) 0.77
Latent classes of course in Alzheimer's disease and predictors: the Cache County Dementia Progression Study. Int J Geriatr Psychiatry (2014) 0.87